ADDENDUM TO LICENSE AGREEMENT
Exhibit 10.29
ADDENDUM TO LICENSE AGREEMENT
This Addendum, effective as of 9 February 2018, is hereby made a part of the License Agreement entered into as of 3 July 2017 (“Agreement”) between Aptorum Therapeutics Limited (formerly known as APTUS Therapeutics Limited), hereinafter “Aptorum” on the one part and
| (1) | PolyU Technology and Consultancy Co. Ltd. (“PTeC”), |
| (2) | The Royal Institution for the Advancement of Learning/XxXxxx University (“McGill”), |
| (3) | Xxxxx State University (“WSU”), |
| (4) | H. Xxx Xxxxxxx Cancer Center and Research Institute Inc. (“MCC”) and |
| (5) | The Chinese University of Hong Kong (“CUHK”) |
are hereinafter referred to collectively as the “Licensors”.
WHEREAS, the Parties have entered into a License Agreement dated 3 July 2017 whereby Licensors have licensed certain patent rights to APTUS Therapeutics Limited as set out in the Agreement:
WHEREAS, APTUS Therapeutics Limited changed its company name to Aptorum Therapeutics Limited effective from 19 September 2017;
WHEREAS, the company name change will have no impact on the Agreement and Aptorum will continue to perform all of its obligations under the Agreement;
WHEREAS, it is in the mutual best interests of Aptorum and Licensors to amend the Agreement to reflect this company name change; and
WHEREAS, all parties agree to amend said Agreement. NOW, THEREFORE, the parties hereto agree as follows:
| 1) | Effective as of 19 September 2017 APTUS Therapeutics Limited changed its legal company name to Aptorum Therapeutics Limited. |
| 2) | Aptorum will continue to perform all of its duties, responsibilities, and obligations under the Agreement. |
| 3) | Licensors hereby consent to continuing the Agreement with Aptorum. |
| 4) | Where the term APTUS Therapeutics Limited shall appear in the original Agreement as amended, the term shall hereinafter mean and refer to Aptorum Therapeutics Limited. |
| 5) | Except as expressly amended hereby, all the remaining provisions of the Agreement shall remain in full force and effect. |
| 1 |
In Witness whereof the parties hereto have signed this Agreement on the date first above written.
SIGNED for and on behalf of
| PolyU Technology and Consultancy Co. Ltd. | |
| /s/ Xxxxxxx Xxx | |
| Signature | |
| Dr. Xxxxxxx Xxx | |
| Printed Name | |
| Director | |
| Title | |
| 12 JAN 2018 | |
| Date |
[The remainder of this page is intentionally left blank.]
| 2 |
In Witness whereof the parties hereto have signed this Agreement on the date first above written.
SIGNED for and on behalf of
The Royal Institution for the Advancement of Learning/XxXxxx University
| /s/ Xxxxxx Xxxxx | |
| Signature | |
| Xxxx. Xxxxxx Xxxxx | |
| Printed Name | |
| Vice-Principal Research & Innovation | |
| Title | |
| 11/14/17 | |
| Date |
[The remainder of this page is intentionally left blank.]
| 3 |
In Witness whereof the parties hereto have signed this Agreement on the date first above written.
SIGNED for and on behalf of
Xxxxx State University
| /s/ Xxxx Xxxxxx | |
| Signature | |
| Xxxx Xxxxxx, PhD | |
| Printed Name | |
| Associate Vice President Technology Committee | |
| Title | |
| Nov 3, 2017 | |
| Date |
[The remainder of this page is intentionally left blank.]
| 4 |
In Witness whereof the parties hereto have signed this Agreement on the date first above written.
SIGNED for and on behalf of
H. Xxx Xxxxxxx Cancer Center and Research Institute Inc.
| /s/ Xxxxx X. Xxxx | |
| Signature | |
| Xxxxx X. Xxxx, PhD | |
| Printed Name | |
| Associate Center Director, Translational Science | |
| Title | |
| 11/6/17 | |
| Date |
[The remainder of this page is intentionally left blank.]
| 5 |
In Witness whereof the parties hereto have signed this Agreement on the date first above written.
SIGNED for and on behalf of
The Chinese University of Hong Kong
| /s/ Xxxxxx X.X. Xx | |
| Signature | |
| Xxxxxx X.X. Xx (Prof) | |
| Printed Name | |
| Director | |
| Title | |
| 03 JAN 2018 | |
| Date |
[The remainder of this page is intentionally left blank.]
| 6 |
